Product launched in France to tell difference between COVID-19 and winter flu

Clinical diagnostics company Novacyt – one of many healthcare companies whose shares have surged during the pandemic – announced on Thursday a new product to allow people to differentiate the COVID-19 virus from common winter diseases.

Novacyt said its new ‘Winterplex’ test panel includes two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV).

“We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases,” Novacyt CEO Graham Mullis said.

Discover more from The Dispatch

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights